Artelo Biosciences, Inc. is advancing three novel drug candidates targeting lipid signaling and the endocannabinoid system, including ART27.13 in Phase 1b/2a trials for cancer anorexia. Despite promising early-stage data, the company faces acute liquidity constraints—holding $0.6 million in cash versus $4 million in current liabilities—and sustained operational losses exceeding $11 million annually. With no revenues or mature products, its capital-intensive development plan and reliance on external financing underpin critical risks. Investors should monitor clinical milestones and financing developments amid persistent cash flow deficits and equity erosion.